New cancer capsule begins first human testing
NCT ID NCT07269145
Summary
This is the first time researchers are testing the experimental drug TQB3122 in people. The study aims to find the safest dose and check for side effects in 86 adults with advanced cancers that have stopped responding to standard treatments. Researchers will also gather early information about whether the capsule might help control tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Meizhou People's Hospital (Meizhou Academy of Medical Sciences)
NOT_YET_RECRUITINGMeizhou, Guangdong, 514031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Tenth People's Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200072, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sichuan Cancer Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.